The Spark, Medicon Village
223 81 Lund, Sweden
In June 2022, Diagonal Bio was granted a patent by the European Patent Office (EP3987059B1) for “a DNA/RNA detection platform”. The patent protects the core technology that combines molecular biology and electrochemistry used for the detection of genetic markers in essentially any type of genetic material. Once validated in key global markets, the patent provides protection for Diagonal Bio’s core technology until 2041.
Strong exclusivity protection
Diagonal Bio’s platform technology received patent approval in Europe 20221, which provides exclusivity protection until 2041.
Diagonal Bio has also registered a design protection for the cartridge in 20222, which provides additional protection linked to the sale of the consumable used in the system’s unit of analysis.
The Company is seeking coverages in the main global markets for both the patent and design protection.